FGF basic/bFGF 蛋白, Human (154a.a, His)

FGF-2 is a member of the fibroblast family involved in bone healing, cartilage repair, bone repair, and nerve regeneration. FGF-2 is also a mitotic promoter that accelerates cell proliferation. FGF-2 regulates immune processes by specifically targeting tyrosine kinase receptors and activating the FGF/FGFR signaling pathway. For example, FGF-2 is involved in the JAK-STAT signaling pathway to regulate cartilage metabolism and also activates ERK signaling to promote cartilage regeneration. FGF-2 combined with FGFR1/3 promoted degeneration and repair of articular cartilage, respectively^[1]. FGF-2 is also a known carcinogen in GBM, which contributes to glioma growth and vascularization^[2].FGF basic/bFGF Protein, Human (154a.a, His), consists of 154 amino acids, produced by E.coli with tag free.

FGF-2/bFGF 是成纤维细胞家族的成员，与肝素具有高亲和力。FGF-2在肌腱至骨愈合、软骨修复、骨修复和神经再生中发挥重要作用。FGF-2 特异性结合酪氨酸激酶受体并激活 FGF/FGFR 信号通路。随后，FGF-2通过转导其他经典途径影响细胞增殖、分化和凋亡以及免疫调节。例如，FGF-2通过调节JAK-STAT信号通路来调节软骨代谢。FGF-2 还充当有丝分裂启动子，加速细胞增殖。因此，（1）FGF-2是韧带/肌腱损伤愈合过程中重要的生长因子。体外实验显示，低剂量FGF-2可刺激骨髓间充质干细胞的增殖和分化，并上调I/III型胶原和纤连蛋白的mRNA表达。然而，高剂量的 FGF-2 不会刺激细胞外基质 (ECM) 蛋白增殖和基因表达。(2)FGF-2也是软骨修复中的内源性和内在生长因子。FGF-2 与硫酸乙酰肝素蛋白多糖结合并储存在关节软骨的 ECM 中。当软骨受损或退化时，ECM迅速释放FGF-2并激活ERK信号通路，促进软骨再生。FGF-2与其特定受体结合表现出双相效应。FGF-2与FGFR3联合促进关节软骨的修复。FGF-2 与 FGFR1 联合促进关节软骨退化^[1]。FGF-2 在颗粒细胞和丘细胞以及肝细胞癌细胞中表达，但在非癌性肝组织中不表达。这揭示了 FGF-2 在脑肿瘤，特别是胶质母细胞瘤中的作用。据研究，FGF-2是GBM中已知的致癌因素。FGF-2 增强胶质母细胞瘤干细胞的自我更新，有助于胶质瘤的生长和血管化^[2]。FGF-2蛋白在某些物种中高度保守，人FGF-2蛋白序列与大鼠、小鼠和牛的相似性分别为97.4%、95.45%和98.71%。

FGF-2 (重组人源蛋白; 3 ng/mL, 30 ng/mL; 7-28 d) 在 3 ng/mL 时触发双相骨髓基质细胞 (BMSC) 反应，在第 7 天促进细胞增殖达到峰值，在第 14 和 28 天，显著增强 I 型胶原、III 型胶原、纤维连接蛋白和 α-平滑肌肌动蛋白 mRNA 表达。但在 30 ng/mL 时无明显作用^[3]。

Measured in a cell proliferation assay using NIH-3T3 mouse fibroblast cells.The ED₅₀ for this effect is 0.157-0.542 ng/mL, corresponding to a specific activity is >1.85×10⁶ U/mg.

• 
  Measured in a cell proliferation assay using NIH-3T3 mouse fibroblast cells.The ED₅₀ for this effect is 0.213 ng/mL, corresponding to a specific activity is 4.695×10⁶ U/mg.

Human

E. coli

N-6*His

P09038-4 (A135-S288)

2247  [NCBI]

AAGSITTLPALPEDGGSGAFPPGHFKDPKRLYCKNGGFFLRIHPDGRVDGVREKSDPHIKLQLQAEERGVVSIKGVCANRYLAMKEDGRLLASKCVTDECFFFERLESNNYNTYRSRKYTSWYVALKRTGQYKLGSKTGPGQKAILFLPMSAKS

Approximately 19 kDa

• 
  Greater than 95% as determined by reducing SDS-PAGE.

无菌粉末

Lyophilized from after extensive dialysis against PBS, pH 7.4 or PBS, 300 mM NaCl, pH 7.4, 5% trehalose, 5% mannitol and 0.01% Tween 80.

<1 EU/μg, determined by LAL method.

It is not recommended to reconstitute to a concentration less than 100 μg/mL in ddH₂O. For long term storage it is recommended to add a carrier protein (0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose).

Stored at -20°C for 2 years. After reconstitution, it is stable at 4°C for 1 week or -20°C for longer (with carrier protein). It is recommended to freeze aliquots at -20°C or -80°C for extended storage.

Room temperature in continental US; may vary elsewhere.

• [1]. Zhang J, et al. FGF2: a key regulator augmenting tendon-to-bone healing and cartilage repair. Regen Med. 2020 Sep;15(9):2129-2142.  [Content Brief]

  [2]. Jimenez-Pascual A, et al. FGF2: a novel druggable target for glioblastoma? Expert Opin Ther Targets. 2020 Apr;24(4):311-318.  [Content Brief]

  [3]. Hankemeier S, et al. Modulation of proliferation and differentiation of human bone marrow stromal cells by fibroblast growth factor 2: potential implications for tissue engineering of tendons and ligaments. Tissue Eng. 2005 Jan-Feb;11(1-2):41-9.  [Content Brief]